Tuberculosis (TB) remains a global emergency and is now the most important cause of death due to infectious disease. In 2016, 10.4 million people developed active TB, of whom 1.7 million died. An estimated 490,000 people had multidrug-resistant TB (MDR-TB), of which 6% had extensively drug-resistant TB (XDR-TB). Available treatment regimens cure only 50% of patients with MDR-TB and 30% of patients with XDR-TB (see Related links). These regimens also are of long duration, have severe and sometimes irreversible side effects, and are associated with poor patient adherence, treatment failure, high mortality, further acquisition of drug resistance and long-term functional disability. There is therefore a major need for the development of novel TB drugs and regimens -a key World Health Organization (WHO) End TB Strategy goal for 2025. Here, we overview the potential of the current TB pipeline with this goal in mind, with a focus on therapeutic strategies for drug-resistant TB (DR-TB).
Near-term goals and progress There are several key unmet needs and challenges for DR-TB therapies. First, we require more effective all-oral regimens for DR-TB that have shorter treatment durations and are less toxic. Better still would be a universal regimen that is effective for both drug-susceptible (DS-TB) and DR-TB. Second, we need TB drugs that can be used safely together and with other medicines -especially antiretroviral drugs used to treat HIV infection, given how common co-infection with HIV and TB is. Third, accurate information is required on drug-drug interactions and drug use in specific patient groups, such as children, pregnant women and the immunocompromised. Fourth, new strategies are required to reduce lung tissue damage and prevent the long-term functional disability associated with MDR-TB. Fifth, we need to combat the emergence of resistance to new TB drugs, by identifying gene mutations and molecular drug targets that counteract resistance.
Concerted efforts of researchers, pharmaceutical companies, advocates and funders have supported the growth of the development pipeline for TB therapies in recent years (Supplementary Figure 1 and  Supplementary Table 2) , spearheaded by the accelerated regulatory approval of two new drugs: the diarylquinoline bedaquiline, which targets mycobacterial energy production (in 2012), and the nitroimidazole delamanid, which targets cell wall synthesis and energy production (in 2014). Five other novel TB drugs are in phase II or phase III trials: the nitroimidazole pretomanid, the oxazolidinones delpazolid and sutezolid (which target bacterial protein synthesis), the ethylenediamine SQ-109 (which targets cell wall synthesis) and the benzothiazinone PBTZ169 (which targets cell wall synthesis by inhibiting DprE1). Several drugs already approved for other indications are also being evaluated in phase II and phase III trials for TB, including the riminophenazine clofazimine (which targets ion transport and bacterial respiration), the fluoroquinolones levofloxacin and moxifloxacin (which target gyrase subunit A (GyrA) of the bacterial DNA gyrase heterotetramer) and the oxazolidinone linezolid. Harnessing this pipeline, 12 phase II or phase III trials of new drugs and regimens for DR-TB have been initiated since 2012 (Supplementary Figure 1) . Here, we highlight a selection of trials for which success may have a substantial impact on several of the unmet needs highlighted above.
The phase II NC-005 trial, which began in November 2014, has an arm that is evaluating an all-oral DR-TB combination regimen of bedaquiline, pretomanid, moxifloxacin and pyrazinamide (BPaMZ). BPaMZ could be potent enough to shorten treatment duration. Final results are expected later in 2018. The single-arm NiX-TB trial, which began in March 2015 in people with XDR-TB, reported dramatic preliminary results in 2017 with a high rate of relapse-free cure and low rates of mortality and irreversible toxicity after 6 to 9 months of treatment with 1 bedaquiline, pretomanid and high-dose linezolid (which was dose-adjusted following toxicity; higher doses are more effective but also more toxic). In November 2017, accrual to NiX was closed upon the opening of a trial known as NC-007 or ZeNiX, a phase III four-arm trial of bedaquiline, pretomanid and linezolid, testing two doses (1,200 mg or 600 mg) and two durations (6 months or 2 months) of daily linezolid in 180 people with XDR-TB.
A phase II trial known as NC-008 or SimpliciTB will open in late 2018, enrolling 150 people with DS-TB to compare 4 months of BPaMZ with 6 months of standard therapy, and including a DR-TB arm with 6 months of the same four drugs. Data are being collated on longterm safety outcomes in participants who have received bedaquiline both in clinical trials or through compassionate use or expanded access programmes. There is increasing assurance that there is no sign yet of an increased risk of mortality, although pharmacovigilance will continue to consider the drug's long half-life and prolongation of the QTc interval, which is a risk factor for life-threatening cardiac arrhythmias.
There are several other ongoing trials of bedaquiline and delamanid in new combination regimens in patients with MDR-TB and XDR-TB (Supplementary  Table 3 ). In December 2016, a phase III five-arm trial known as endTB, which has an adaptive design, began evaluating 9 months of treatment with all-oral combinations of bedaquiline, linezolid, moxifloxacin, clofazimine and delamanid in 750 people with fluoroquinolone-sensitive MDR-TB in Georgia, Kazakhstan, Kyrgyzstan, Lesotho and Peru. In January 2017, a two-stage, five-arm phase II/III study known as TB PRACTECAL began evaluating 6 months of various combinations of bedaquiline, pretomanid, moxifloxacin, linezolid and clofazimine compared with standard WHO treatment in 630 people with MDR-TB or XDR-TB in Belarus, South Africa and Uzbekistan. Finally, the AIDS Clinical Trials Group protocol A5343, which is assessing the QTc prolongation, safety, tolerability and pharmacokinetics of bedaquiline and delamanid -including in people receiving antiretroviral therapy for HIV -will complete accrual in 2018. Such drug-drug interaction studies are crucial for understanding drug safety as new TB drugs are combined in large phase III trials and rolled out in country programmes.
Early-stage advances
Several promising new drugs for use in MDR-TB are in early clinical development (Supplementary Table 2 ). They seem to have improved potency, bioavailability and less toxicity than previous agents in their classes. New agents that target mycobacterial energy production include the imidazopyridine Q203, which will enter phase II trials in 2018. A new riminophenazine, TBI-166, will entire phase I testing as a less toxic alternative to clofazimine. A new potent diarylquinoline, TBAJ-587, that has less QTc-prolongation potential than bedaquiline is also being developed. New inhibitors of cell wall synthesis that target DprE1 include the benzothiazinone PBTZ169, which is entering phase II trials, and OPC-167832, for which phase I trials to evaluate synergy with delamanid are under way. Phase I trials of BTZ-043, a new benzothiazinone, are planned. Finally, among the new agents that target mycobacterial protein synthesis are oxazolidinones and the oxaborole GSK-3036656, which is the first in a new class of TB drug. Phase II trials of delpazolid, sutezolid and GSK-3036656 are ongoing, as are phase I trials of contezolid.
Improving evaluation
As more drug candidates become available, new biomarkers that predict cure, relapse and long-term treatment outcomes (such as sputum-based transcriptomics, positron emission tomography and computed tomography (PET-CT) imaging, and blood-based or urinebased assays) are required to enable more efficient clinical trial designs to evaluate multiple new drugs at a time. Inadequate capacity to perform clinical trials to support registration of new regimens for TB treatment in TB-endemic regions will become problematic. This lack of clinical trial capacity in TB-endemic regions needs to be addressed by expanding beyond the current dominance of Western groups in leading the trials. Increased investment in local capacity-building, knowledge transfer and upgrades of infrastructure to good clinical and laboratory practice standards is required to address this.
International agencies, national governments and communities should come together to develop innovative funding and market incentive mechanisms to promote and support new TB drug development and rapid adoption of new regimens that are shown to provide direct benefit to the patient and health services. It is anticipated that the unprecedented United Nations General Assembly high-level meeting on TB in New York later this year (see Related links) will lead to increased resources for global TB-control activities, including the development and evaluation of new TB therapies.
